Sankyo Company, Limited

Japan Display Inc.

Metabasis Therapeutics, Inc.

Toshihiko Fujiwara

Takashi Fujita

Hiroyoshi Horikoshi

Kunio Wada

Takao Yoshioka

Hiroaki Yanagisawa

Minoru Oguchi

Koichi Fujimoto

Hayato Kurasawa

Daisuke Ito

Shinji Yoshioka

Makoto Takamura

Hidehito Honma

Hiroshi Mizuhashi

Mark D Erion

Hiroyuki Koike

Yoshio Tsujita

Hiroshi Nishino

Masaaki Miyamoto

Toshio Sada

Haruo Iwabuchi

Paul D Van Poelje

Shinichi Kurakata

Masaharu Fukami

Mitsuya Sakurai

Takashi Izumi

Tsunemichi Hosokawa

Koichi Iwasaki

Junichiro Fukushige

Naoyuki Maeda

According to one embodiment, a display device includes a display panel having a display area, a first substrate opposed to the display panel, an adhesive layer arranged between the display panel and the first substrate, a first electrode formed at the first substrate in a peripheral area arranged along at least a part of an outer edge of the display area, a second electrode formed at the display panel in the peripheral area. In the display device, the first electrode includes a first portion which is opposed to the second electrode and a second portion which is not opposed to the second electrode, and the adhesive layer is interposed between the first portion and the second electrode.

Display device

A touch detection device includes a substrate, a plurality of drive electrodes arranged on a plane parallel to the substrate and in a first region in which an image is displayed, and a plurality of touch detection electrodes configured to generate a capacitance between the touch detection electrodes and the drive electrodes. At least one touch detection electrode among the touch detection electrodes includes a first part arranged in the first region and a second part arranged in a second region adjacent to the first region. The drive electrodes are sequentially supplied with the first drive signal to detect a conducting body in contact with or close to the first region in a first touch detection mode, and the touch detection electrodes are supplied with a second drive signal to detect a conducting body in contact with or close to the second region in a second touch detection mode.

Touch detection device, display device with touch detection function, and cover member

A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.

Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes

Thiazolidine-2,4-dione hydrochloride salt, pharmaceutical compositions thereof and treatment method therewith

A pharmaceutical composition comprising as its active ingredients one or more drugs selected from the group consisting of angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors, and one or more insulin resistance improving agents exhibits excellent arteriosclerotic progress inhibitory effects, and is useful as a drug, particularly as a drug for the prevention or treatment of arteriosclerosis. The invention also provides a method for the treatment or prophylaxis of arteriosclerosis by administering in combination (i) at least one of said angiotensin II receptor antagonists or angiotensin converting enzyme inhibitors and (ii) one or more insulin resistance improving agents to a mammal suffering from or susceptible to arteriosclerosis. The invention also provides kits containing at least a first container which comprises at least one angiotensin II receptor antagonists and/or angiotensin converting enzyme inhibitor and a second container which contains at least one insulin resistance improving agent.

Pharmaceutical compositions and methods for the treatment of arteriosclerosis

&agr;-substituted carboxylic acid derivatives

Amine derivative compounds

Amidocarboxylic acid derivatives

Substituted fused heterocyclic compound

Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.

Method for the treatment and prevention of hyperuricemia

A method for preventing or treating autoimmune diseases (excluding type I diabetes) by administering an insulin resistance improving substance as an active ingredient.

Method for preventing and for treating autoimmune disease

Compound of formula (I): ##STR1## [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulphur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an integer of from 1 to 5] have hypoglycemic and anti-diabetic activities.

Heterocyclic compounds having anti-diabetic activity and their use

Phenylalkylcarboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 represents an alkyl group and the like, R.sup.2 represents an alkylene group, R.sup.3 represents a hydrogen atom and the like, X represents a substituted or unsubstituted aryl group and the like, Y represents an oxygen atom and the like, Z represents an alkylene group and the like, and W represents an alkyl group and the like), the pharmacologically acceptable salts thereof or the pharmacologically acceptable esters thereof are useful as therapeutic or preventive agents for hyperglycemia and the like.

Phenylalkylcarboxylic acid compounds and compositions for treating

Compounds of formula (I): ##STR1## [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrinidinyl group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxo-oxadiazolidin-2-ylmethyl or N-hydroxyureidom ethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and m is an inzeger of from 1 to 5] have hypoglycemic and anti-diabetic activities.

Heterocyclic compound having anti-diabetic activity

Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen or alkyl; R.sup.2 is alkylene; R.sup.3 is hydrogen, alkyl, alkoxy, alkylthio, halogen, nitro group, amino group, monoalkylamino, dialkylamino, aryl, or aralkyl; X is aryl, or aromatic heterocyclic; Y is oxygen, sulfur or a group of formula &gt;N--R.sup.4, in which R.sup.4 is hydrogen, alkyl or acyl; and Z is a group of formula (Za), (Zb), (Zc) or (Zd): ##STR2## and salts thereof can be used to treat or prevent are included those arising from hyperlipidemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistant non-IGT (NGT), non-diagnostic glucose tolerance, insulin resistance, diabetic complications, fatty liver, polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM); in addition the compounds of the present invention have aldose reductase inhibitory activity.

Oxime derivatives, their preparation and their therapeutic use

Growing community of inventors

Tokyo, Japan

Toshihiko Fujiwara